Orthofix Medical Inc. (OFIX) |
| 11.58 -0.31 (-2.61%) 07-17 16:00 |
| Open: | 11.67 |
| High: | 11.84 |
| Low: | 11.25 |
| Volume: | 329,355 |
| Market Cap: | 468(M) |
| PE Ratio: | -47.17 |
| Exchange: | NASDAQ Global Select |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 14.06 |
| Resistance 1: | 12.04 |
| Pivot price: | 10.89 |
| Support 1: | 10.07 |
| Support 2: | 8.85 |
| 52w High: | 16.99 |
| 52w Low: | 8.85 |
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
| EPS | -1.500 |
| Book Value | 10.780 |
| PEG Ratio | 48.83 |
| Gross Profit | 14.500 |
| Profit Margin (%) | -7.27 |
| Operating Margin (%) | -6.75 |
| Return on Assets (ttm) | -3.3 |
| Return on Equity (ttm) | -13.4 |
Wed, 15 Jul 2026
Orthofix to Report Second Quarter 2026 Financial Results - Business Wire
Sun, 05 Jul 2026
Enterprise value to revenue forward of Orthofix Medical Inc. – NASDAQ:OFIX - TradingView
Fri, 03 Jul 2026
Orthofix Medical Sees Medicare Reimbursement Policy Restored - The Globe and Mail
Fri, 03 Jul 2026
Orthofix Medical (OFIX) Among the Best Small-Cap Growth Stocks To Buy Now - Yahoo Finance
Thu, 02 Jul 2026
Orthofix (OFIX) expects Medicare bone stimulator reimbursement to return to prior levels - Stock Titan
Mon, 29 Jun 2026
Orthofix (OFIX) Moves 5.1% Higher: Will This Strength Last? - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |